binimetinib   Click here for help

GtoPdb Ligand ID: 7921

Synonyms: ARRY 162 | ARRY-162 | ARRY-438162 | MEK-162 | MEK162 | Mektovi®
Approved drug PDB Ligand
binimetinib is an approved drug (FDA and EMA (2018))
Compound class: Synthetic organic
Comment: Binimetinib is a potent non-ATP competitive inhibitor of MEK1/2 kinase activity [3] (link directly to abstract 794 online here).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 88.41
Molecular weight 440.03
XLogP 3.23
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F
Isomeric SMILES OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F
InChI InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
1. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A et al.. (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Lancet Oncol, 14 (3): 249-56. [PMID:23414587]
2. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R et al.. (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol, 19 (5): 603-615. [PMID:29573941]
3. Pheneger J, Wallace, E, Marlow, A Hurley B, Lyssikatos J, Bendele AM, Lee PA. (2006)
Characterization of ARRY-438162, a Potent MEK Inhibitor in Combination with Methotrexate or Ibuprofen in In Vivo Models of Arthritis.[abstract].
American College of Rheumatology 2006 Annual Scientific Meeting,: Abstract 794.